Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment

Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment

Published: Just now By Mateen Dalal

Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development Reports confirm that Applied Therapeutics Inc. has recently unveiled the initia....

Amazon Air to commence flights to Anchorage International Airport

Amazon Air recently announced that it plans to begin flights to Ted Stevens Anchorage International Airport. The airport published a post on twitter, confirming that the carrier will operate daily services to the Alaskan hub, utilizing its ....

Security concerns drive Microsoft to ban internal use of Slack, AWS

Microsoft believes various versions of Slack do not offer sufficient controls to protect its intellectual property Microsoft has reportedly barred its more than 100,000 employees from using the free version of Slack. Apparently, Microsoft ....

JetBlue to add long-range Airbus jets to expand services to Europe

·         JetBlue, in April, had given confirmation of its first service to Europe starting 2021 ·         Its new Airbus jet would serve cities ....

Harley-Davidson inks deal to make smaller motorcycles in China

The new bikes would have a 338cc engine, by far the smallest engine model Harley has ever made, and will be sold in China by late 2020. American motorcycle manufacturer Harley-Davidson has reportedly announced to have inked a partners....

MobiKwik, DT One team up to offer mobile recharge services worldwide

It will be the first time DT One will have mobile recharge originating from India through their network MobiKwik, an India based fintech platform, recently announced that it is partnering with DT One, a global network for mobile recharge a....

RIBOMIC confirms positive results from SUSHI study in wet AMD patients

Phase 1/2a trial of RBM-007 was successfully conducted, yielding top-line results   Seven out of nine subjects showed a considerable improvement in Central Retinal Thickness Clinical stage pharmaceutical company RIBOMIC has recen....